No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
We Think Prime Medicine (NASDAQ:PRME) Needs To Drive Business Growth Carefully
Express News | Prime Medicine Inc Files for Resale of up to 11 Mln Common Shares by the Selling Stockholder - SEC Filing
Prime Medicine Initiated at Market Outperform by JMP Securities
JMP Securities Initiates Prime Medicine(PRME.US) With Buy Rating, Announces Target Price $10
Prime Medicine, Inc.: Innovative Gene Editing Platform With Significant Market Potential
Guggenheim Reiterates Buy on Prime Medicine, Maintains $18 Price Target